REM Sleep Behavior Disorder Market to grow at a CAGR of 6.7% during 2024-2028
The REM Sleep Behavior Disorder Market is expected to grow at a CAGR of 6.7% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 438.6 million. The REM sleep behavior disorder market is experiencing substantial growth, driven by the incorporation of advanced technologies such as artificial intelligence (AI) and machine learning (ML). These innovations are significantly enhancing sleep disorder detection and management, presenting lucrative opportunities for enhanced patient outcomes. AI and ML models have revolutionized the analysis of extensive sleep-related datasets, enabling the development of precise diagnostic models for various sleep disorders, including insomnia and sleep apnea. These predictive models utilize demographic and physiological data, such as age, sex, and body mass index (BMI), to identify individuals at risk of developing sleep disorders, thereby streamlining diagnosis and treatment processes.
Get more information on REM Sleep Behavior Disorder Market by requesting a sample report
Technavio analysts predict that the Hospitals subsegment will lead the End-user segment during 2024 and 2028 Hospitals serve as vital business entities in the management and treatment of REM Sleep Behavior Disorder (RBD). They provide specialized care to patients through multidisciplinary teams consisting of sleep specialists, neurologists, and other healthcare professionals. Hospitals are equipped with advanced diagnostic tools, such as video-polysomnography (vPSG), which enable the precise identification of RBD. This diagnostic method detects muscle atonia loss during REM sleep, a key indicator of RBD. The comprehensive diagnostic services offered in hospitals ensure accurate differentiation of RBD from other sleep disorders, thereby contributing significantly to effective treatment and patient care.
Here are the various ways based on which the market is segmented:
There are several factors that are causing the market to flourish rising prevalence of neurological disorders
Learn which are the obstacles that the market is experiencing in the way of its growth by accessing the free PDF report
REM Sleep Behavior Disorder (RBD) is a parasomnia characterized by the loss of muscle atonia during REM sleep, leading to acting out of dreams and abnormal behaviors. This neurological disorder is associated with various conditions, including Parkinson's disease, Multiple System Atrophy, and Narcolepsy. The global medical technology market for RBD is anticipated to grow significantly due to increasing healthcare expenditure on neurological disorders. The epidemiology of RBD is complex, with both idiopathic and symptomatic forms. Symptomatic RBD is often associated with neurodegenerative diseases, while idiopathic RBD occurs without an apparent underlying condition. The prevalence of RBD is estimated to be around 0.5% in the general population, with higher rates in older adults and those with neurodegenerative disorders. Current medical therapies for RBD include antidepressant medication, primarily clomipramine and melatonin. However, these conventional therapies have limitations, and emerging drugs, such as pridopidine and solifenacin, are under investigation. The pipeline for RBD drugs is growing, with several marketed drugs and new treatments in development. Understanding the disease and its diagnosis involves recognizing the symptoms, including dream replay, parasomnia, and muscle atonia. The treatment algorithm for RBD includes a multidisciplinary approach, including medication, lifestyle modifications, and safety precautions to prevent injury. The ongoing research and development in this area aim to improve the diagnosis, treatment, and understanding of RBD and its associated conditions.
The REM Sleep Behavior Disorder (RBD) market falls under the broader global pharmaceuticals sector, encompassing entities involved in research and development (R&D) or production of various drug categories, including generics, non-generics, and veterinary drugs. According to Technavio's market analysis, the healthcare industry's size is determined by the consolidated revenue generated by manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. The expansion of the global pharmaceuticals market is anticipated to be influenced by several key factors. One such factor is the increasing elderly population. By 2050, approximately one-quarter of the US population and by 2030 in Europe, are projected to be over the age of 60 years. This demographic shift is expected to fuel the demand for pharmaceutical solutions, including those for RBD.
The REM Sleep Behavior Disorder Market is experiencing significant growth, fueled by the rising prevalence of neurological disorders. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
